A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 10, Issue 3, 2011, Pages 210-216

  Wong, Nan Soon ^a,b   Fernando, Nishan H ^a,c   Bendell, Johanna C ^a,d   Morse, Michael A ^a   Blobe, Gerard C ^a   Honeycutt, Wanda ^a   Pang, Herbert ^a   Hurwitz, Herbert I ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c Georgia Cancer Specialists   (United States)

^d SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

Bevacizumab; Capecitabine; Metastatic colorectal cancer; Oxaliplatin; Phase II

Indexed keywords

BEVACIZUMAB; CAPECITABINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL EVALUATION; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INFECTION; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SENSORY NEUROPATHY; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

EID: 80052456693     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2011.03.018     Document Type: Article

References (45)

1. M.M. Center, A. Jemal, and R.A. Smith Worldwide variations in colorectal cancer CA Cancer J Clin 59 2009 366 378
2. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate Advanced Colorectal Cancer Meta-Analysis Project J Clin Oncol 30 1992 896 903
3. A.R. Curreri, F.J. Ansfield, and F. Mc Iver Clinical studies with 5-fluorouracil Cancer Res 18 1958 478 484
4. C. Heidelberger, N.K. Chaudhuri, and P. Danneberg Fluorinated pyrimidines, a new class of tumour-inhibitory compounds Nature 179 1957 663 666
5. F. Levi, B. Perpoint, and C. Garufi Oxaliplatin activity against metastatic colorectal cancer A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate Eur J Cancer 29 1993 1280 1284 (Pubitemid 23169897)
6. D. Machover, E. Diaz-Rubio, and A. de Gramont Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines Ann Oncol 7 1996 95 98 (Pubitemid 26051870)
7. Y. Becouarn, M. Ychou, and M. Ducreux Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients Digestive Group of French Federation of Cancer Centers J Clin Oncol 16 1998 2739 2744 (Pubitemid 28363039)
8. E. Diaz-Rubio, J. Sastre, and A. Zaniboni Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study Ann Oncol 9 1998 105 108 (Pubitemid 28125772)
9. T. Andre, C. Louvet, and E. Raymond Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen Ann Oncol 9 1998 1251 1253 (Pubitemid 28552817)
10. F.A. Levi, R. Zidani, and J.M. Vannetzel Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial J Natl Cancer Inst 86 1994 1608 1617 (Pubitemid 24336347)
11. A. de Gramont, A. Figer, and M. Seymour Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938 2947 (Pubitemid 30644117)
12. D. Cunningham, S. Pyrhonen, and R.D. James Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer Lancet 352 1998 1413 1418 (Pubitemid 28510874)
13. P. Rougier, E. Van Cutsem, and E. Bajetta Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer Lancet 352 1998 1407 1412 (Pubitemid 28510873)
14. J.Y. Douillard, D. Cunningham, and A.D. Roth Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 2000 1041 1047 (Pubitemid 30162806)
15. C.H. Kohne, E. van Cutsem, and J. Wils Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986 J Clin Oncol 23 2005 4856 4865 (Pubitemid 46223990)
16. L.B. Saltz, J.V. Cox, and C. Blanke Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer Irinotecan Study Group N Engl J Med 343 2000 905 914
17. C. Tournigand, T. Andre, and E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2003 229 237
18. M.M. Borner, D. Dietrich, and R. Stupp Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer J Clin Oncol 20 2002 1759 1766 (Pubitemid 34273264)
19. J. Cassidy, J. Tabernero, and C. Twelves XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer J Clin Oncol 22 2004 2084 2091 (Pubitemid 41095141)
20. E. Diaz-Rubio, T.R. Evans, and J. Tabemero Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors Ann Oncol 13 2002 558 565 (Pubitemid 34461139)
21. T. Makatsoris, H.P. Kalofonos, and G. Aravantinos A phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancer Int J Gastrointest Cancer 35 2005 103 109 (Pubitemid 41272207)
22. A.A. Martoni, C. Pinto, and F. Di Fabio Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial) Eur J Cancer 42 2006 3161 3168 (Pubitemid 44854520)
23. P. Pfeiffer, H. Sorbye, and H. Ehrsson Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil Ann Oncol 17 2005 252 258
24. W. Scheithauer, G.V. Kornek, and M. Raderer Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 21 2003 1307 1312 (Pubitemid 46606408)
25. A.F. Shields, M.M. Zalupski, and J.L. Marshall Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial Cancer 100 2004 531 537 (Pubitemid 38124770)
26. M. Zeuli, C. Nardoni, and M.S. Pino Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer Ann Oncol 14 2003 1378 1382 (Pubitemid 37185283)
27. M. Ducreux, J. Bennouna, and M. Hebbar Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer Int J Cancer 128 2011 682 690
28. J. Cassidy, S. Clarke, and E. Diaz-Rubio Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J Clin Oncol 26 2008 2006 2012
29. E. Diaz-Rubio, J. Tabernero, and A. Gomez-Espana Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial J Clin Oncol 25 2007 4224 4230 (Pubitemid 47548562)
30. W. Scheithauer, G.V. Kornek, and M. Raderer Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer Ann Oncol 13 2002 1583 1589 (Pubitemid 35331455)
31. H.S. Hochster, L.L. Hart, and R.K. Ramanathan Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study J Clin Oncol 26 2008 3523 3529
32. L.B. Saltz, S. Clarke, and E. Diaz-Rubio Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
33. H.I. Hurwitz, L. Fehrenbacher, and J.D. Hainsworth Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer J Clin Oncol 23 2005 3502 3508
34. F.F. Kabbinavar, J. Hambleton, and R.D. Mass Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer J Clin Oncol 23 2005 3706 3712
35. B.J. Giantonio, P.J. Catalano, and N.J. Meropol Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 2007 1539 1544 (Pubitemid 46733080)
36. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342 (Pubitemid 38702844)
37. A. Grothey, M.M. Sugrue, and D.M. Purdie Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) J Clin Oncol 26 2008 5326 5334
38. E. Van Cutsem, F. Rivera, and S. Berry Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study Ann Oncol 20 2009 1842 1847
39. Genentech Inc Avastin Prescribing Information 2009 http://www.gene.com
40. Common Terminology for Adverse Events, version 3.0 http://ctep.cancer. gov/protocoldevelopment/electronic-applications/docs/ctcaev3.pdf
41. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
42. D.G. Haller, J. Cassidy, and S.J. Clarke Potential regional differences for the tolerability profiles of fluoropyrimidines J Clin Oncol 26 2008 2118 2123
43. E. Chu Clinical colorectal cancer: oral chemotherapy comes of age Clin Colorectal Cancer 1 2001 75
44. H. Hurwitz, Y.Z. Patt, and D. Henry Phase III study of standard triweekly versus dose-dense biweekly capecitabine (C) + oxaliplatin (O) + bevacizumab (B) as first-line treatment for metastatic colorectal cancer (mCRC): XELOX-A-DVS (dense versus standard): interim analysis J Clin Oncol 27 2009 (suppl; abstr 4078)
45. A.C. Reinacher-Schick, S. Kubicka, and W. Freier Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): a randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604) J Clin Oncol 26 2008 (May 20 suppl; abstr 4030)